Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

MSD and Daiichi Sankyo have revealed some of the ... according to Charles Rudin of Memorial Sloan Kettering Cancer Center in New York, who presented the data at WCLC. On safety, there was a ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

at 08:05 Daiichi Sankyo to Showcase TURALIO® Research in Patients ... at 08:05 Medidata Unveils Transformative Solutions and Collaborations at NEXT New York, Driving Paradigm Shift in Life Sciences ...

Viasat, Inc. , a global communications company, today announced the launch of its innovative home and mobile broadband service in Mexico. Viasat, in collaboration with Altán, the Mexican ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...